readthroughSign in
Oct 21, 2026Clinical readoutUpdated

Neogen raises fiscal 2027 revenue, EBITDA outlook on first-quarter growth

Neogen lifted full-year guidance after first-quarter core revenue grew 8.1% and said Petrifilm manufacturing and a pending Zoetis divestiture remain on schedule.

Neogen Corporation reported fiscal 2027 first-quarter results on October 6, 2026 and raised its outlook for the year. The company said it is increasing its financial guidance for fiscal year 2027 and is now expecting total revenue in the range of $885 million to $890 million and Adjusted EBITDA in the range of $181 million to $183 million1, up from prior guidance of $880 million to $885 million in revenue and $180 million to $182 million in Adjusted EBITDA.

On manufacturing, Neogen said it remains on track to manufacture saleable Petrifilm product and begin its planned multi-quarter manufacturing transition of Petrifilm to its Lansing manufacturing site beginning in November 2026, after completing full validation of its first SKU in August 2026, demonstrating the ability to produce product that meets required quality and performance standards.1

The company also disclosed a new partnership, saying it announced a strategic collaboration with and an equity investment in Hinalea Imaging Corp. to develop digital imaging solutions for food safety and quality inspection.1 Neogen said the work aims to speed development of hyperspectral imaging applications that could automate parts of food inspection and testing processes and help customers interpret results faster and more consistently.1

On its pending divestiture, Neogen said it is still working to close the previously announced sale of its global Genomics business to Zoetis Inc., noting the deal remains subject to customary closing conditions and pending regulatory reviews, which are currently expected to conclude by the end of December 2026.1

Financially, revenues for the first quarter were $222.8 million, growth of 6.5% when compared to $209.2 million in the prior-year first quarter, while core revenue, which excludes the impacts of foreign currency translation as well as divestitures and discontinued product lines, increased by 8.1%.1 The company posted a net loss of $11.9 million, or $(0.05) per diluted share, compared to net income of $36.3 million, or $0.17 per diluted share, in the prior-year quarter, with the prior-year gain driven primarily by the non-cash gain recognized on the divestiture of the Cleaners & Disinfectants business.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.